
Sign up to save your podcasts
Or


California's Fair Debt Collection Practices Act has long been a critical framework for protecting consumers from abusive or unfair debt collection practices. Recently, however, Governor Gavin Newsom signed into law SB 1286 on September 24, 2024, expanding these protections to certain commercial debts. This significant legislative change has considerable implications for lenders, financial advisors, attorneys, and debt collectors.
Read the full article.
About the authors:
Justin T. Bradley
Scott J. Hyman, CIPP (US/E), CIPM, CIPT
When it comes to Big Data, you're the product. So what laws are in place to protect you, and what are your options?
Read the full article.
About the author:
Theodore F. Claypoole
The U.S. Department of Justice recently updated its guidance on corporate compliance programs, and the implications for businesses are significant.
This revised guidance is a critical resource for compliance officers, legal professionals, and corporate executives. It reflects the DOJ's ongoing commitment to addressing emerging risks, encouraging employee reporting, and ensuring equitable resource allocation for compliance functions.
Read the full article.
About the authors:
Audrey N. Karman
Luke Cass
Website cookies have become an integral part of how online businesses operate, providing vital data that enhances user experience and marketing strategies. However, the increasing scrutiny over privacy concerns has made it crucial for businesses to navigate the complex regulatory landscape governing the use of cookies.
Read the full article.
About the authors:
Nadia G. Aram
Kyle G. Kessler, CIPP/E
By now, we all know that Generative AI models are trained on massive amounts of data, much of which is collected from the Internet, as well as other sources.
This AI is also generating tons of new content, much of which ends up online. But what happens when this AI-generated content is used again to train the AI models?
Read the full article.
About the author
Dr. Christian E. Mammen
In the ever-evolving landscape of mergers and acquisitions, the past few years have ushered in significant changes as businesses navigate economic turbulence. One notable shift in this sphere is the increasing prevalence of earnout deals. These arrangements, which link a portion of the purchase price to the future performance of the acquired entity, have become a pivotal strategy in bridging valuation gaps and managing risk.
Read the full article.
About the authors:
Patrick T. Strubbe
Yuechu Li*
Recently, the quest for prolonging human life and enhancing the quality of our later years has gained substantial momentum. With advancements in aging biology, the dream of accessing the "fountain of youth" seems more achievable than ever. However, despite promising scientific breakthroughs, regulatory challenges continue to hinder the availability of anti-aging therapies to the general public.
Read the full article.
About the author:
Matt Quinn, Ph.D.
When selling intellectual property, the common setup usually includes getting an upfront payment plus future royalty payments, which are a slice of the revenue earned from the IP. This approach can give sellers a steady income over time. However, while royalties offer ongoing revenue and a stake in the IP's success, relying only on future royalties involves risks.
Read the full article.
About the author
Edward L. Schnitzer
When privacy meets complexity, the legal landscape shifts. The recent Ninth Circuit decision in Calhoun v. Google has thrown a spotlight on the critical importance of clear and comprehensible privacy notices.
Read the full article.
About the authors:
Jack F. Altura
Tomio Narita
In recent years, the potential of MDMA as a treatment for Post-Traumatic Stress Disorder has generated significant interest within the medical community. The drug, commonly known as ecstasy, has moved beyond its controversial recreational use to become a promising candidate for therapeutic purposes. However, the path to its approval has encountered significant hurdles. Recently, the FDA rejected Lykos Therapeutics' application for MDMA therapy, leaving many to wonder about the future of this approach.
Read the full article.
About the author:
Madeline Campbell, Ph.D.
From the publisher's feed
Welcome to Womble Perspectives, where we explore a wide range of topics from the latest legal updates to industry trends to the business of law. Our team of lawyers, professionals and occasional…